Literature DB >> 27745912

Perioperative high dose rate brachytherapy (PHDRB) in previously irradiated head and neck cancer: Results of a phase I/II reirradiation study.

Maria Isabel Martínez-Fernández1, Juan Alcalde2, Mauricio Cambeiro1, German Valtueña Peydró1, Rafael Martínez-Monge3.   

Abstract

BACKGROUND AND
PURPOSE: This study was undertaken to determine the feasibility of salvage surgery and PHDRB in patients with previously irradiated, recurrent head and neck cancer or second primary tumors arising in a previously irradiated field. METHODS AND MATERIALS: Sixty-three patients were treated with surgical resection and PHDRB. The PHDRB dose was 4Gy b.i.d.×8 (32Gy) for R0 resections and 4Gy b.i.d.×10 (40Gy) for R1 resections, respectively. Further external beam radiotherapy or chemotherapy was not given.
RESULTS: Resections were categorized as R0 in 7 patients (11.1%) and R1 in 56 (88.9%). Thirty-four patients with R1 resections (54.0%) had microscopically positive margins, and 22 patients (34.9%) had close margins. Thirty-two patients (50.8%) developed RTOG grade 3 or greater adverse events including 3 fatal events. After a median follow-up of 6.8years, the 5-year locoregional control rate and 5-year overall survival rates were 55.0% and 35.6%, respectively.
CONCLUSIONS: Surgical resection and PHDRB is a successful treatment strategy in selected patients with previously irradiated head and neck cancer. Long-term locoregional control can be achieved in a substantial number of cases despite a high rate of inadequate surgical resections although at the expense of substantial toxicity.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Head and neck cancer; High dose rate; Perioperative; Prior radiation therapy; Reirradiation

Mesh:

Year:  2016        PMID: 27745912     DOI: 10.1016/j.radonc.2016.08.023

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

Review 1.  A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery.

Authors:  Julianna Rodin; Voichita Bar-Ad; David Cognetti; Joseph Curry; Jennifer Johnson; Chad Zender; Laura Doyle; David Kutler; Benjamin Leiby; William Keane; Adam Luginbuhl
Journal:  J Contemp Brachytherapy       Date:  2018-10-31

2.  Permanent Interstitial Cesium-131 Brachytherapy in Treating High-Risk Recurrent Head and Neck Cancer: A Prospective Pilot Study.

Authors:  Michael Kharouta; Chad Zender; Tarun Podder; Rod Rezaee; Pierre Lavertu; Nicole Fowler; Jason Thuener; Shawn Li; Kate Clancy; Zhengzheng Xu; Min Yao
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

3.  Multi-Institutional Study Validates Safety of Intraoperative Cesium-131 Brachytherapy for Treatment of Recurrent Head and Neck Cancer.

Authors:  Adam Luginbuhl; Alyssa Calder; David Kutler; Chad Zender; Trisha Wise-Draper; Jena Patel; Michael Cheng; Vidhya Karivedu; Tingting Zhan; Bhupesh Parashar; Shuchi Gulati; Min Yao; Pierre Lavertu; Vinita Takiar; Alice Tang; Jennifer Johnson; William Keane; Joseph Curry; David Cognetti; Voichita Bar-Ad
Journal:  Front Oncol       Date:  2021-11-26       Impact factor: 6.244

4.  Perioperative high dose rate brachytherapy in head and neck cancers: case report and review of clinical application.

Authors:  Amit Bahl; Roshan K Verma; Naresh K Panda; Arun S Oinam; Jerry R John; Satinder Kaur; Pramod Kumar; Sushmita Ghoshal; Gaurav Trivedi; Jaimanti Bakshi
Journal:  BJR Case Rep       Date:  2021-04-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.